School With 50 Locations Uses Electric Shock Devices on Autistic Children — the FDA Wants to Ban the Devices

Key Takeaways

• FDA proposes ban on electric shock devices for autistic children
• Judge Rotenberg Center, 50 sites, sole U.S. user of shock therapy
• FDA cites lack of evidence and severe physical/psychological risks
• 2022 omnibus act gives FDA power to ban devices for specific uses
• If finalized, transition period will allow patients to shift to alternative treatments

Pulse Analysis

The FDA’s renewed push to prohibit electric shock devices marks a watershed moment in the regulation of aversive behavioral therapies. While electroconvulsive therapy remains permissible for certain psychiatric conditions, the agency distinguishes the punitive shock systems used on individuals with autism and other developmental disabilities as lacking scientific validation and posing “unreasonable and substantial” risks. This regulatory stance builds on a 2020 ban that was overturned due to statutory limits, but the 2022 Food and Drug Omnibus Reform Act now equips the FDA with the authority to target specific device uses, reviving its ability to act decisively.

At the center of the controversy is the Judge Rotenberg Educational Center (JRC), a Massachusetts‑based institution that operates roughly 50 residential locations—the only U.S. school still employing the shock therapy. Decades of investigative reporting have documented multiple deaths, lawsuits, and allegations that students receive shocks for minor infractions unrelated to genuine aggression. JRC’s own research underpins the limited evidence cited by supporters, yet the FDA’s review highlights methodological flaws and a lack of independent validation. The institution’s legal victories, including a 2021 appellate ruling and a 2023 state supreme court decision, have kept the practice alive despite mounting public outcry and over 8,500 critical comments during the agency’s notice‑and‑comment period.

Should the proposed rule become final, it will outlaw the marketing and use of these devices, while granting a transition window for affected individuals to move to less invasive interventions such as positive behavior support, sensory integration, or medication under medical supervision. The ban would not only protect a vulnerable cohort from physical injury and trauma but also reinforce broader disability‑rights principles that demand dignity and consent in treatment. Industry stakeholders are likely to monitor the outcome closely, as the decision could influence future FDA actions on other contentious medical devices and shape best‑practice standards across behavioral health services.